Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Astellas Pharma Europe Ltd
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN STABLE HEART TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF® BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT EVEROLIMUS
The primary objective of this study is to compare two immunosuppressive therapy regimens with respect to their influence on estimated Glomerular Filtration Rate (eGFR) at 52 weeks after conversion to ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN WITH SIMPLIFIED BLADDER TRAINING VERSUS SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN ALONE IN A PROSPECTIVE, RANDOMIZED, PARALLEL GROUP, OVERACTIVE BLADDER SYMPTOM STUDY
To assess the efficacy of solifenacin succinate 5mg od plus simplified bladder training compared with solifenacin succinate 5mg od alone at 8 weeks in subjects with overactive bladder symptoms
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
A study in which multiple applications of Qutenza are investigated in patients with nerve pain
To assess the safety of repeated treatments of QUTENZA in subjects with peripheral neuropathic pain.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
This clinical study investigates the effect of fidaxomicin in comparison to vancomycin in adult patients with an infection of Clostridium difficile, and are using medicinal products that suppress the immune system
The primary objective of the study is to demonstrate superiority of fidaxomicin versus vancomycin for the sustained clinical cure of Clostridium difficile Infection (CDI) in adult patients receiving i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
AN OPEN, RANDOMISED, MULTICENTRE CLINICAL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF STEROID WITHDRAWAL WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND DACLIZUMAB AGAINST TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS IN CHILDREN AFTER KIDNEY TRANSPLANTATION
The primary objective of this study is to investigate the impact of early corticosteroid withdrawal in paediatric renal transplant patients on growth expressed as change in height SDS from baseline to...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED POST-TRANSPLANT) AND MMF WITH OR WITHOUT A MONOCLONAL ANTI-IL2R ANTIBODY (BASILIXIMAB)
The primary objective of this study is to compare the three therapy regimens with regard to renal function.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
Studying the safe and effective use of Modigraf (a tacrolimus-containing medicine in the form of granules that can be suspended in fluid) to prevent rejection of transplants in children
F506-CL-0404A: To monitor the safety and efficacy of Modigraf® (tacrolimus granules) in stable paediatric allograft recipients. F506-CL-0404B: To monitor dose changes and tacrolimus whole blood tro...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
A study to compare the blood levels of Tacrolimus in children who already have a transplant when they are switched from anti-rejection therapy with Prograf to therapy with Advagraf, including checking safety and effectivity over a longer period after switching
To compare the steady state AUC0-24h of tacrolimus for Advagraf® with that of Prograf® in stable pediatric allograft recipients after 1:1 (mg:mg) conversion from Prograf® to Advagraf®
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
A study of an approved granule formulation of tacrolimus to examine the absorption and excretion by the body of newly transplanted paediatric patients
To determine the pharmacokinetics (PK) of tacrolimus following oral administration of Modigraf®, after the first oral dose and at steady state in paediatric subjects undergoing de novo allograft tran...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
AN OPEN, RANDOMISED, MULTICENTRE, EXPLORATORY CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS IN COMBINATION WITH MONOCLONAL ANTI-IL2R ANTIBODIES OR STEROIDS IN HCV POSITIVE PATIENTS UNDERGOING LIVER ALLOGRAFT TRANSPLANTATION
The objective of this exploratory study is to evaluate the impact of the elimination of the steroid administration upon viral HCV load at 12 months measured by quantitative serum HCV-RNA determination...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
Suivant